Kv beta 1.3 assembly with Kv alpha 1.5 modifies the channel's gating and pharmacology, providing a molecular basis for designing new drugs targeting cardiovascular diseases.
Absolute Event Rate: 0% vs 0%
Kv1.5 channels are homotetramers of alpha-pore subunits mainly present in human atrium and pulmonary vasculature. Thus, Kv1.5 is a pharmacological target for cardiovascular diseases. Kv beta 1.3 assemblies with Kv alpha 1.5 and modifies its gating and pharmacology. A further knowledge of alpha-beta interactions and pharmacology will lead a better design of new drugs.
González et al. (Sun,) reported a other. Kv beta 1.3 assembly with Kv alpha 1.5 modifies the channel's gating and pharmacology, providing a molecular basis for designing new drugs targeting cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: